You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractThere are a number of rare neurodegenerative diseasesincluding Amyotrophic Lateral SclerosisALSand Huntington s DiseaseHDfor which there is no available or effective therapy and which lead to significant morbidity and mortality ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists to prevent Charcot Marie Tooth diseaseA Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractCharcot Marie ToothCMTdisease typeA is an incurableprimarily pediatricautosomal dominant neuromuscular degenerative disease caused by mutations in the mitofusinMFNgeneThere are currently no disease altering treatmentsMitochondria in Mot ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A mobile technology to extend the reach of primary care for opioid misuse

    SBC: Rissana, LLC            Topic: NIDA

    Project Summary Opioid use disorderOUDhas reached epidemic levels in the United Stateswith catastrophic resultsmore Americans died from opioid overdoses inandthan in the entirety of the Vietnam WarPrimary care providersPCPsserve a critical role in combatting this epidemicbecause they see patients who misuse opioids but are not yet dependent in addition to those who are already dependentHoweverther ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Advancement of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)

    SBC: Accuronix Therapeutics Inc            Topic: 102

    Project Summary Abstract Pancreatic cancer is a devastating disease with a very lowyear survival rateTherapeutic options are limited in efficacy and many have substantial toxicityTargeted drug delivery may improve the therapeutic index of cancer drugs by enhancing drug localization to the cancer cell while minimizing off target side effectsreceptors are highly expressed in pancreatic and other can ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. The Rapid-Production of the High-Performance and Affordable Cadmium Telluride and Cadmium Zinc Telluride for Medical Imaging Applications

    SBC: Radiation Detection Technologies, Inc.            Topic: NIBIB

    The high spatial resolution and energy resolution of cadmium zinc tellurideCZTand cadmium tellurideCdTecompared to that of scintillatorsoffers superior image quality in Nuclear medicine and X rayimaging applicationsi eSPECTPETCTBone DensitometryOncologyDental imagingAirportsecurityetcEven after two decades of researchCZT and CdTe remain the desired choice for roomtemperature radiation detectionbut ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Novel insulin-sensitizing NASH/diabetes drugs.

    SBC: BIOIO, LLC            Topic: 300

    Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesityrelated metabolic diseases constitute a significant public health burdenThe increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obeseIn additionobesity is also associated with accumulation of lipid in the liver parenchymahepat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy

    SBC: Medical Guidance Systems LLC            Topic: 102

    Abstract The proposed drug development will result in the design and development of a ligand targeted liposomeLTLthat will aid in the targeted delivery of therapeutics to patients with Non Small Cell Lung CancerNSCLCWe propose an innovative active targeting strategy and our technology exploits the stress response that occurs within the cancer cells following exposure to ionizing radiationThis lipo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Novel, Potent and Metabolically Stable Oxytocin Analogues to Treat Obesity

    SBC: Oxt Therapeutics, Inc.            Topic: 300

    The goal of this project is to develop novel oxytocinOXTanalogues with improved safety and efficacy vsnative OXT for the treatment of obesity and related metabolic disordersObesity is an increasing health care burden in the US andeven though it is recognized as a significant risk factor for developing cardiovascular disease and typediabetesthere has been limited progress in developing safe and eff ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A New Small-Molecule Kinase Inhibitor for Airway Disease

    SBC: NuPeak Therapeutics, Inc.            Topic: NHLBI

    Abstract NuPeak Therapeutics Incis a biotechnology companyC corporationdesigned to deliver a first in class smallmolecule kinase inhibitorSMKIfor therapeutic use in humansThe present Project is aimed at an inhibitor for treatment of respiratory airway disease especially due to asthma and COPDwhich remain leading causes of morbidity and mortality in the U Sand worldwide despite current therapeutic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Use of mimotope vaccine technology to develop vaccines against bacterial pathogens

    SBC: ZenVax LLC            Topic: NIAID

    ABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government